Please login to the form below

Not currently logged in
Email:
Password:

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

Oxford Biomedica taps Microsoft to progress gene therapy delivery tech

It’s the approach that is used in Novartis’ Kymriah, a CAR-T therapy that was approved last year for the treatment of those with relapsed or refractory large B-cell ... lymphoma. However, Novartis was a prime example of the complex manufacturing

Latest news

  • CMS proposes coverage scheme for CAR-T therapies CMS proposes coverage scheme for CAR-T therapies

    The information could then be used to decide what CAR-Ts are most beneficial to patients and should be funded in future. ... So far two CAR-Ts have reached the US market, but there are dozens more coming through the clinical and preclinical pipeline.

  • AbbVie enters BCMA race with Teneobio deal AbbVie enters BCMA race with Teneobio deal

    of CAR-Ts, they could emerge as the new standard of care, not having the complicated and expensive manufacturing process with the cell therapies, and also potentially producing fewer side-effects. ... The company says its platform comes with an added

  • CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

    Boysen adds: “CAR T-cell therapy is expensive, however the treatment is specific to each individual and could be a potential cure for some, although it is early days. ... CAR-Ts involve taking white blood cells from the patient, which are then

  • Sanofi and Regeneron re-jig immuno-oncology deal Sanofi and Regeneron re-jig immuno-oncology deal

    That particular protein has emerged as the most promising new target in multiple myeloma, and is now been pursued by a pack of competing pipeline candidates: CAR-Ts from Celgene/Bluebird,

  • Novartis buys CellforCure to bolster cell, gene therapy Novartis buys CellforCure to bolster cell, gene therapy

    It says the deal would “would bolster CAR-T cell therapy manufacturing capacity with potential to expand to other cell and gene therapies in Novartis pipeline.”. ... CAR-Ts like Kymriah are challenging to produce, as they require harvesting T cells

More from news
Approximately 8 fully matching, plus 20 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics